Journal of Spectroscopy

Journal of Spectroscopy / 2003 / Article

Open Access

Volume 17 |Article ID 283731 | https://doi.org/10.1155/2003/283731

Didier Esquieu, Jean-Marie Péloponèse, Sandrine Opi, Catherine Gregoire, Jean de Mareuil, Jennifer Watkins, Grant Campbell, Jean-Pierre Dunot, James Sturgis, Myriam Witvrouw, Christophe Pannecouque, Erik de Clercq, Mickaël Montembault, Vo-Thanh Giang, Monique Villiéras, Valérie Fargeas, Jacques Lebreton, Erwann P. Loret, "Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design", Journal of Spectroscopy, vol. 17, Article ID 283731, 7 pages, 2003. https://doi.org/10.1155/2003/283731

Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design

Abstract

Tat is a regulatory HIV-1 protein, which has the particularity to be secreted very early by HIV-infected cells. The extra cellular roles of Tat are suspected to be the main cause of the maintenance of reservoirs of HIV-infected cells and the failure of actual AIDS therapies to eradicate HIV. This study describes the rationale used to design molecules that bind to a target area containing an hydrophobic pocket identified in the 2D-NMR structure of Tat. Molecules were synthesized and the derivative named TDS2 was shown to be a Tat inhibitor. Fluorescence revealed that TDS2 binds in the target area, which is conserved across five different Tat variants representative of the main HIV-1 subtypes. TDS2 inhibited in vitro HIV-1 replication in human T-cells. Further chemical modifications remain necessary to enhance affinity to Tat and reduce cytotoxicity.

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views122
Downloads356
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.